WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Chinese tourist tower overlooking North Korea could be demolished — Radio Free AsiaTe reo Māori: Govt seeks to halt extra pay for public servants fluent in the languageNorth Korea's Kim Jong Un turns 40 ... maybeFormer Pakistan PM Imran Khan gets 10Chlöe Swarbrick announces she will run for Greens coHomes catch fire as lava spills onto town in IcelandNelson urgently needs revitalisation as economic performance slumpsTe reo Māori: Govt seeks to halt extra pay for public servants fluent in the languageJimmy Lai provided HK$1.5 million loan to activists, court hearsPedestrian dies after being hit by truck in Northland